Sanofi Eyes Using Zantac 360 Most-Recommended Ad Claim With Disclaimer Highlighting Ingredient
Executive Summary
Industry self-regulation group’s appeals board agrees with investigative division’s finding Sanofi didn’t support Zantac 360 “#1 doctor recommended” ad claims. Board declines to consider whether “#1 doctor recommended H2 active ingredient” with “based on generic acid reducer recommendations” disclaimer is supported.
You may also be interested in...
In Second Review Of CeraVe ‘#1 Recommended’ Claim, L’Oreal’s Survey ‘Substantially More Reliable’
With new evidence providing “reasonable basis” for claim support, National Advertising Division reverses course on 2021 decision on J&J challenge of L’Oreal USA’s use of "#1 recommended by dermatologist" claims.
Sanofi Appealing Findings In Review Of Zantac 360 Doctor-Recommended Claims Challenged By J&J
French pharma disagrees with NAD finding, following review of a claims made in online and social media ads, retailers' websites and a TV commercial, that the claim “#1 doctor recommended medicine” for Zantac 360 refers to the brand and not famotidine, also used in other OTC heartburn remedies, including Pepcid.
Sanofi Overcomes Zantac Troubles To Gain Share In US
Sanofi Consumer Healthcare has been gaining share in the US OTC market since October 2020 after putting behind it long running Zantac troubles, according to business head Julie Van Ongevalle.